RYONCIL (Remestemcel-L-rknd)

Remestemcel-L-rknd (Ryoncil) is FDA-approved for the treatment of steroid-refractory acute graftversus-host disease (SR-aGvHD) in pediatric patients greater than or equal to 2 months of age. It contains mesenchymal stromal cells (MSC) from the bone marrow of healthy human adult donors. MSCs inhibit T-cell activation which have a role in the inflammatory response and organ damage associated with acute graft-versus-host disease (aGvHD). <a id="